4DMT: Intravitreal Gene Therapy With 4D-150: Advancing Clinical Evidence of a Potential Backbone Therapy in nAMD and DME

Location: Schubert 1
Date & Time: Saturday, 3rd October, 10:15 – 11:15 CEST
Chairperson(s):
G. Cheung (Singapore)

Speakers:

Presentations:

G. Cheung (Singapore)

10:15  Setting the Stage: Why Continuous Retinal Disease Requires Continuous Treatment

S. Sivaprasad (UK)

10:25  Inside the Design of Gene Therapy: How Fundamental Concepts Drive Mechanisms of Action and Purposeful Design

P. Schlottmann (Argentina)

10:35  Backbone Therapy for nAMD: Redefining Success and How 4D-150 is Positioned to Become Foundational for nAMD Care

D. Sambhara (USA)

10:43  PRISM and 4FRONT: Key Clinical Data and Phase 3 Study Design Rationale

D. Sambhara (USA)

10:55  SPECTRA: A Paradigm Shift for Treatment of DME

G. Cheung (Singapore)

10:55  Panel Discussion

G. Cheung (Singapore)

11:09  Audience Questions

Back to Main Programme